Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
Jacqueline S. Garcia(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Jerome Ritz(Dana-Farber Cancer Institute), Andrew M. Brunner(Harvard University), Eric S. Winer(Providence College), Marlise R. Luskin(Dana-Farber Cancer Institute), Jacquelyn O. Wolff(Dana-Farber Cancer Institute), Rebecca Leonard(Dana-Farber Cancer Institute), Corey Cutler(Harvard University), Yael Flamand(Dana-Farber Cancer Institute), Vincent T. Ho(Dana-Farber Cancer Institute), Asad Bashey, Livius Penter(Dana-Farber Cancer Institute), Taylor Robertson(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Martha Wadleigh(Dana-Farber Cancer Institute), Ilene Galinsky(Dana-Farber Cancer Institute), Yohei Arihara(Sapporo Medical University), Joseph H. Antin(Dana-Farber Cancer Institute), Scott J. Rodig(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Paul Koller(City of Hope), Brian A. Jonas(Cellular Therapeutics (United Kingdom)), Richard M. Stone(Dana-Farber Cancer Institute), Michael Keng(University of Virginia), Kathleen L. Pfaff(Dana-Farber Cancer Institute), Lourdes Mendez(Beth Israel Deaconess Medical Center), Benjamin Tomlinson(University Hospitals Cleveland Medical Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Howard Streicher(National Cancer Institute), Nicole Cullen(Dana-Farber Cancer Institute), Alexandra Savell(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Cited by 51
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k